Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 558

The DOI matches its Crossref record; 310 of the 310 references it cites were found in a registry or an index.

Inducible Nitric Oxide Synthase and Inflammatory Diseases

Open access
Zamora, Ruben, Vodovotz, Yoram, Billiar, Timothy R.·2000·Molecular Medicine
DOI 10.1007/bf03401781
Open this paper in CoChat — free account

Abstract

Nitric oxide (NO) is a colorless gas at room temperature and one of the simplest molecules known, yet it has been implicated in a wide variety of regulatory mechanisms ranging from vasodilatation and blood pressure control to neurotransmission. It is also involved in nonspecific immunity and participates in the complex mechanism of tissue injury as a major mediator of inflammatory processes and apoptosis ( 1 ). This work focuses on the complex role of NO produced by the inducible form of nitric oxide synthase (iNOS) in inflammatory and autoimmune diseases. Although the earliest studies in the field suggested that NO is a strictly pro-inflammatory macrophage product, it is clear from the current literature that, in fact, NO is made by numerous cell types and is often anti-inflammatory. Much of this dichotomy can be explained by the particular responses of given cells involved in the inflammatory response, but another variable involves the complex chemistry in which NO can participate. As we outline below, various facets of the immune response can be examined from these perspectives.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/bf03401781

Cites

310 of 310 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 55

  1. Groeneveld PH, Kwappenberg KM, Langermans JA, et al. (1997) Relation between pro- and anti-inflammatory cytokines and the production of nitric oxide (NO) in severe sepsis. Cytokine. 9: 138–142. · doi:10.1006/cyto.1996.0147
  2. Pender BS, Chen H, Ashton S, et al. (1996) Transforming growth factor β 1 alters rat peritoneal macrophage mediator production and improves survival during endotoxic shock. Eur. Cytokine Netw. 7: 137–142.
  3. Salvemini D, Seibert K, Marino MH. (1996) PG release, as a consequence of NO-driven COX activation, contributes to the proinflammatory effects of NO. Drugs News Perspect. 4: 204–219.
  4. Bulut V, Severn A, Liew FY. (1993) Nitric oxide production by murine macrophages is inhibited by prolonged elevation of cyclic AMP. Biochem. Biophys. Res. Commun. 195: 1134–1138. · doi:10.1006/bbrc.1993.2162
  5. Kepka-Lenhart D, Chen L-C, Morris SM. (1996) Novel actions of aspirin and sodium salicylate: discordant effects on nitric oxide synthesis and induction of nitric oxide synthase mRNA in a murine macrophage cell line. J. Leukoc. Biol. 59: 840–846. · doi:10.1002/jlb.59.6.840
  6. Harbrecht BG, Kim YM, Wirant EA, et al. (1997) Timing of prostaglandin exposure is critical for the inhibition of LPS- or IFN-γ-induced macrophage NO synthesis by PGE2. J. Leukoc. Biol. 61: 712–720. · doi:10.1002/jlb.61.6.712
  7. Cuzzocrea S, Costantino G, Zingarelli B, et al. (1999) Protective effects of poly (ADP-ribose) synthase inhibitors in zymosan-activated plasma induced paw edema. Life Sci. 65: 957–964. · doi:10.1016/s0024-3205(99)00325-2
  8. Wong HR, Finder JD, Wasserloos K, et al. (1996) Transcriptional regulation of iNOS by IL-1 β in cultured rat pulmonary artery smooth muscle cells. Am. J. Physiol. 271: L166–L171.
  9. Shoker AS, Yang H, Murabit MA, et al. (1997) Analysis of the in vitro effect of exogenous nitric oxide on human lymphocytes. Mol. Cell Biochem. 171: 75–83. · doi:10.1023/a:1006815430622
  10. Taylor-Robinson AW. (1997) Counter-regulation of T helper 1 cell proliferation by nitric oxide and interleukin-2. Biochem. Biophys. Res. Commun. 233: 14–19. · doi:10.1006/bbrc.1997.6386
  11. Kosonen O, Kankaanranta H, Lahde M, et al. (1998) Nitric oxide-releasing oxatriazole derivatives inhibit human lymphocyte proliferation by a cyclic GMP-independent mechanism. J. Pharmacol. Exp. Ther. 286: 215–220. · doi:10.1016/s0022-3565(24)37577-9
  12. Gabbai FB, Boggiano C, Peter T, et al. (1997) Inhibition of inducible nitric oxide synthase intensifies injury and functional deterioration in autoimmune interstitial nephritis. J. Immunol. 159: 6266–6275. · doi:10.4049/jimmunol.159.12.6266
  13. Hoffman RA, Langrehr JM, Berry LM, et al. (1996) Bystander injury of host lymphoid tissue during murine graft-versus-host disease is mediated by nitric oxide. Transplantation 61: 610–618. · doi:10.1097/00007890-199602270-00016
  14. Falzarano G, Krenger W, Snyder KM, et al. (1996) Suppression of B-cell proliferation to lipopolysaccharide is mediated through induction of the nitric oxide pathway by tumor necrosis factor-α in mice with acute graft-versus-host disease. Blood 87: 2853–2860. · doi:10.1182/blood.v87.7.2853.bloodjournal8772853
  15. Winlaw DS, Schyvens CG, Smythe GA, et al. (1995) Selective inhibition of nitric oxide production during cardiac allograft rejection causes a small increase in graft survival. Transplantation 60: 77–82. · doi:10.1097/00007890-199507150-00015
  16. Tanaka S, Kamiike W, Ito T, et al. (1995) Generation of nitric oxide as a rejection marker in rat pancreas transplantation. Transplantation 60: 713–717. · doi:10.1097/00007890-199510150-00017
  17. Santos LL, Morand EF, Yang Y, et al. (1997) Suppression of adjuvant arthritis and synovial macrophage inducible nitric oxide by N-iminoethyl-l-ornithine, a nitric oxide synthase inhibitor. Inflammation 21: 299–311. · doi:10.1023/a:1027397816209
  18. Miesel R, Kurpisz M, Kroger H. (1996) Suppression of inflammatory arthritis by simultaneous inhibition of nitric oxide synthase and NADPH oxidase. Free Radic. Biol. Med. 20: 75–81. · doi:10.1016/0891-5849(95)02026-8
  19. Gassner R, Buckley MJ, Georgescu H, et al. (1999) Cyclic tensile stress exerts antiinflammatory actions on chondrocytes by inhibiting inducible nitric oxide synthase. J. Immunol. 163: 2187–2192. · doi:10.4049/jimmunol.163.4.2187
  20. Borderie D, Hilliquin P, Hernvann A, et al. (1999) Apoptosis induced by nitric oxide is associated with nuclear p53 protein expression in cultured osteoarthritic synoviocytes. Osteoarthritis. Cartilage. 7: 203–213. · doi:10.1053/joca.1998.0209
  21. Rothe H, Kolb H. (1999) Strategies of protection from nitric oxide toxicity in islet inflammation. J. Mol. Med. 77: 40–44. · doi:10.1007/s001090050298
  22. Whittle BJ. (1997) Nitric oxide-a mediator of inflammation or mucosal defence. Eur. J. Gastroenterol. Hepatol. 9: 1026–1032. · doi:10.1097/00042737-199711000-00002
  23. Mourelle M, Vilaseca J, Guarner F, et al. (1996) Toxic dilatation of colon in a rat model of colitis is linked to an inducible form of nitric oxide synthase. Am. J. Physiol. 270: G425–G430.
  24. Dimmeler S, Haendeler J, Nehls M, et al. (1997) Suppression of apoptosis by nitric oxide via inhibition of interleukin-1β-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J. Exp. Med. 185: 601–607. · DOI · Paper page
  25. Scott L, Kerr A, Haydock D, et al. (1997) Subendothelial proteoglycan synthesis and transforming growth factor β distribution correlate with susceptibility to atherosclerosis. J. Vasc. Res. 34: 365–377. · doi:10.1159/000159245
  26. Tsuji M, Dimov VB, Yoshida T. (1995) In vivo expression of monokine and inducible nitric oxide synthase in experimentally induced pulmonary granulomatous inflammation. Evidence for sequential production of interleukin-1, inducible nitric oxide synthase, and tumor necrosis factor. Am. J. Pathol. 147: 1001–1015.
  27. Nozaki Y, Hasegawa Y, Takeuchi A, et al. (1997) Nitric oxide as an inflammatory mediator of radiation pneumonitis in rats. Am. J. Physiol. 272: L651–L658.
  28. Moncada S. (1994) Nitric oxide. J. Hypertens. Suppl. 12: S35–S39.
  29. Ruschitzka F, Corti R, Noll G, et al. (1999) A rationale for treatment of endothelial dysfunction in hypertension. J. Hypertens. Suppl 17: S25–S35.
  30. Wigand R, Meyer J, Busse R, et al. (1997) Increased serum NG-hydroxy-l-arginine in patients with rheumatoid arthritis and systemic lupus erythematosus as an index of an increased nitric oxide synthase activity. Ann. Rheum. Dis. 56: 330–332. · doi:10.1136/ard.56.5.330
  31. Harper L, Savage CO. (1999) Mechanisms of endothelial injury in systemic vasculitis. Adv. Nephrol. Necker Hosp. 29: 1–15.
  32. Borderie D, Hilliquin P, Hernvann A, et al. (1999) Nitric oxide synthase is expressed in the lymphomononuclear cells of synovial fluid in patients with rheumatoid arthritis. J. Rheumatol. 26: 2083–2088.
  33. Salvatierra J, Escames G, Hernandez P, et al. (1999) Cartilage and serum levels of nitric oxide in patients with hip osteoarthritis. J. Rheumatol. 26: 2015–2017.
  34. Kwon OJ, Kim JH, Kim HC, et al. (1998) Nitric oxide expression in airway epithelial cells in response to tubercle bacilli stimulation. Respirology. 3: 119–124. · doi:10.1111/j.1440-1843.1998.tb00109.x
  35. Rogers DF, Laurent GJ. (1998) New ideas on the pathophysiology and treatment of lung disease. Thorax 53: 200–203. · doi:10.1136/thx.53.3.200
  36. Zamora SA, Amin HJ, McMillan DD, et al. (1997) Plasma l-arginine concentrations in premature infants with necrotizing enterocolitis. J. Pediatr. 131: 226–232. · doi:10.1016/s0022-3476(97)70158-6
  37. Sigge W, Wedel T, Kuhnel W, et al. (1998) Morphologic alterations of the enteric nervous system and deficiency of non-adrenergic non-cholinergic inhibitory innervation in neonatal necrotizing enterocolitis. Eur. J. Pediatr. Surg. 8: 87–94. · doi:10.1055/s-2008-1071128
  38. Beckett CG, Dell’Olio D, Ellis HJ, et al. (1998) The detection and localization of inducible nitric oxide synthase production in the small intestine of patients with coeliac disease. Eur. J. Gastroenterol. Hepatol. 10: 641–647.
  39. Cattell V, Cook T. (1995) The nitric oxide pathway in glomerulonephritis. Curr. Opin. Nephrol. Hypertens. 4: 359–364. · doi:10.1097/00041552-199507000-00013
  40. Lianos EA. (1998) Activation and potential interactions between the arachidonic acid and l-arginine:nitric oxide pathways in glomerulonephritis. Kidney Int. 53: 540–547. · doi:10.1046/j.1523-1755.1998.00792.x
  41. Cattell V. (1999) Nitric oxide and glomerulonephritis. Semin. Nephrol. 19: 277–287.
  42. Wang JS, Tseng HH, Shih DF, et al. (1997) Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis. Nephron 77: 404–411. · doi:10.1159/000190316
  43. Vara E, Arias-Diaz J, Garcia C, et al. (1995) Production of TNF alpha, IL-1, IL-6 and nitric oxide by isolated human islets. Transplant. Proc. 27: 3367–3371.
  44. Pavlovic D, Chen MC, Bouwens L, et al. (1999) Contribution of ductal cells to cytokine responses by human pancreatic islets. Diabetes 48: 29–33. · doi:10.2337/diabetes.48.1.29
  45. Cortesi R, Ascenzi P, Colasanti M, et al. (1998) Cross-enzyme inhibition by gabexate mesylate: formulation and reactivity study. J. Pharm. Sci. 87: 1335–1340. · doi:10.1021/js980079u
  46. Wein AJ. (1997) Nitric oxide and interstitial cystitis. J. Urol. 158: 993.
  47. Bagasra O, Michaels FH, Zheng YM, et al. (1995) Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 92: 12041–12045. · DOI · Paper page
  48. Satoi H, Oka N, Kawasaki T, et al. (1998) Mechanisms of tissue injury in vasculitic neuropathies. Neurology 50: 492–496. · doi:10.1212/wnl.50.2.492
  49. McKenzie RC, Weller R. (1998) Langerhans cells, keratinocytes, nitric oxide and psoriasis [letter; comment]. Immunol. Today 19: 427–428. · doi:10.1016/s0167-5699(98)01290-0
  50. Kolb-Bachofen V, Bruch-Gerharz D. (1999) Langerhans cells, nitric oxide, keratinocytes and psoriasis [letter]. Immunol. Today 20: 289. · doi:10.1016/s0167-5699(98)01411-x
  51. Yamamoto T, Sawada Y, Katayama I, et al. (1998) Increased production of nitric oxide stimulated by interleukin-1beta in peripheral blood mononuclear cells in patients with systemic sclerosis. Br. J. Rheumatol. 37: 1123–1125. · doi:10.1093/rheumatology/37.10.1123
  52. Clough GF. (1999) Role of nitric oxide in the regulation of microvascular perfusion in human skin in vivo. J. Physiol (Lond) 516: 549–557. · doi:10.1111/j.1469-7793.1999.0549v.x
  53. Lafond-Walker A, Chen CL, Augustine S, et al. (1997) Inducible nitric oxide synthase expression in coronary arteries of transplanted human hearts with accelerated graft arteriosclerosis. Am. J. Pathol. 151: 919–925.
  54. Takeichi O, Hayashi M, Tsurumachi T et al. (1999) Inducible nitric oxide synthase activity by interferon-gamma-producing cells in human radicular cysts. Int. Endod. J. 32: 124–130. · doi:10.1046/j.1365-2591.1999.00203.x
  55. Bacman SR, Berra A, Sterin-Borda L et. al. (1998) Human primary Sjogren’s syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. Curr. Eye Res. 17: 1135–1142. · doi:10.1076/ceyr.17.12.1135.5124

Cited by

See all 558

Metadata

Authors
Zamora, R., Vodovotz, Y., & Billiar, T. R.
Venue
Molecular Medicine
Publisher
Springer Science and Business Media LLC
Published
2000-05
Volume
6
Issue
5
Pages
347-373
ISSN
  • 1076-1551 (ISSN-L)
  • 1528-3658
DOI
10.1007/bf03401781
OpenAlex
W1495576061
Cited by
558
References
310
FWCI
3.59
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.